Valuation: Arcturus Therapeutics Holdings Inc.

Market Cap 271M 241M 221M 201M 379M 25.66B 387M 2.64B 1.06B 13.57B 1.02B 996M 42.95B P/E 2026 *
-2.78x
P/E 2027 * -2.57x
Enterprise Value 111M 99.22M 91.01M 82.71M 156M 10.55B 159M 1.08B 435M 5.58B 418M 409M 17.65B EV / Sales 2026 *
5.98x
EV / Sales 2027 * 9.42x
Free-Float
92.01%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Arcturus Therapeutics Holdings Inc.

1 day+13.94%
1 week-3.21%
Current month-1.45%
1 month-16.58%
3 months+81.17%
6 months+25.96%
Current year+77.32%
1 week 9.12
Extreme 9.125
12.44
1 month 9.12
Extreme 9.125
15.17
Current year 5.5
Extreme 5.5
17.96
1 year 5.5
Extreme 5.5
17.96
3 years 5.5
Extreme 5.5
45
5 years 5.5
Extreme 5.5
48.75
10 years 4.11
Extreme 4.11
129.71
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2013
Director of Finance/CFO 71 01/05/2026
Chief Tech/Sci/R&D Officer 65 01/12/2025
Director TitleAgeSince
Chairman 84 27/05/2018
Director/Board Member 67 27/05/2018
Director/Board Member 67 27/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
01/05/26 Free

Chief Financial Officer

100,000 0.3683%
17/12/25 Free

Controller/Auditor

10,000 0.0368%
17/12/25 Free

General Counsel

54,000 0.1989%
Change 5-day change 1-year change 3-year change Capi.($)
+13.94%-3.21%+16.88%-44.48% 271M
+10.00%+5.18%+54.35%+71.20% 60.57B
+1.44%+4.06%+22.70%+101.03% 55.51B
+3.32%+4.11%+14.82%+75.04% 55.22B
+0.46%-2.86%+23.34%+33.77% 43.27B
+6.42%+3.20%+21.14%+105.56% 40.36B
+2.82%+7.24%+236.59%+801.17% 41.63B
-3.79%+19.39%+91.90%+77.13% 33.29B
+5.32%+6.04%+20.27%+52.98% 32.27B
+5.32%+15.84%-40.93%+342.66% 22.91B
Average +4.53%+3.01%+46.11%+161.61% 38.53B
Weighted average by Cap. +3.73%+4.05%+51.55%+169.36%

Financials

2026 *2027 *
Net sales 18.64M 16.6M 15.22M 13.83M 26.04M 1.76B 26.62M 181M 72.81M 933M 69.96M 68.47M 2.95B 28.8M 25.63M 23.51M 21.37M 40.23M 2.72B 41.12M 280M 112M 1.44B 108M 106M 4.56B
Net income -98.13M -87.36M -80.13M -72.83M -137M -9.29B -140M -954M -383M -4.91B -368M -360M -15.54B -115M -102M -93.69M -85.15M -160M -10.86B -164M -1.12B -448M -5.74B -431M -421M -18.17B
Net Debt -160M -142M -130M -119M -223M -15.11B -228M -1.55B -624M -7.99B -599M -587M -25.29B -
Projected Income Statement - Annual - Arcturus Therapeutics Holdings Inc.
Logo Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Employees
109
Date Price Change Volume
04/11/26 $10.88 +14.05% 495,762
03/11/26 $9.540 +0.53% 749,056
02/11/26 $9.490 -13.96% 796,202
30/10/26 $11.03 -9.22% 1,845,017
29/10/26 $12.15 +0.66% 474,762
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Arcturus Therapeutics Holdings Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
9.540USD
Average target price
23.80USD
Spread / Average Target
+149.48%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Arcturus Therapeutics Holdings Inc.
  1. Stock Market
  2. Stocks
  3. ARCT Stock